These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060 [TBL] [Abstract][Full Text] [Related]
3. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. Komatsu H; Tanji E; Sakata N; Aoki T; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M; Furukawa T PLoS One; 2014; 9(2):e87875. PubMed ID: 24498386 [TBL] [Abstract][Full Text] [Related]
4. Constitutive stimulatory G protein activity in limb mesenchyme impairs bone growth. Karaca A; Malladi VR; Zhu Y; Tafaj O; Paltrinieri E; Wu JY; He Q; Bastepe M Bone; 2018 May; 110():230-237. PubMed ID: 29471062 [TBL] [Abstract][Full Text] [Related]
5. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Wilson CH; McIntyre RE; Arends MJ; Adams DJ Oncogene; 2010 Aug; 29(32):4567-75. PubMed ID: 20531296 [TBL] [Abstract][Full Text] [Related]
6. Intragenic suppression of a constitutively active allele of Gsα associated with McCune-Albright syndrome. Tobar-Rubin R; Sultan D; Janevska D; Turcic K; Carroll J; Ooms L; Pals-Rylaarsdam R J Mol Endocrinol; 2013 Apr; 50(2):193-201. PubMed ID: 23288949 [TBL] [Abstract][Full Text] [Related]
7. Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Mariot V; Wu JY; Aydin C; Mantovani G; Mahon MJ; Linglart A; Bastepe M Bone; 2011 Feb; 48(2):312-20. PubMed ID: 20887824 [TBL] [Abstract][Full Text] [Related]
9. Frequency of GNAS R201H substitution mutation in polyostotic fibrous dysplasia: Pyrosequencing analysis in tissue samples with or without decalcification. Shin SJ; Lee SJ; Kim SK Sci Rep; 2017 Jun; 7(1):2836. PubMed ID: 28588314 [TBL] [Abstract][Full Text] [Related]
10. Detection of Rare Somatic GNAS Mutation in McCune-Albright Syndrome Using a Novel Peptide Nucleic Acid Probe in a Single Tube. Lo FS; Chen TL; Chiou CC Molecules; 2017 Nov; 22(11):. PubMed ID: 29104223 [TBL] [Abstract][Full Text] [Related]
11. Induced Khan SK; Yadav PS; Elliott G; Hu DZ; Xu R; Yang Y Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E418-E427. PubMed ID: 29158412 [TBL] [Abstract][Full Text] [Related]
12. Activating GNAS mutations in parosteal osteosarcoma. Carter JM; Inwards CY; Jin L; Evers B; Wenger DE; Oliveira AM; Fritchie KJ Am J Surg Pathol; 2014 Mar; 38(3):402-9. PubMed ID: 24525511 [TBL] [Abstract][Full Text] [Related]
13. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review. Lin YL; Ma R; Li Y J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes. Bekers EM; Eijkelenboom A; Rombout P; van Zwam P; Mol S; Ruijter E; Scheijen B; Flucke U Diagn Pathol; 2019 Feb; 14(1):15. PubMed ID: 30736805 [TBL] [Abstract][Full Text] [Related]
15. Germline-Derived Gain-of-Function Variants of Gs Miyado M; Fukami M; Takada S; Terao M; Nakabayashi K; Hata K; Matsubara Y; Tanaka Y; Sasaki G; Nagasaki K; Shiina M; Ogata K; Masunaga Y; Saitsu H; Ogata T J Am Soc Nephrol; 2019 May; 30(5):877-889. PubMed ID: 30962325 [TBL] [Abstract][Full Text] [Related]
16. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576 [TBL] [Abstract][Full Text] [Related]
17. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. Kawabata H; Ono Y; Tamamura N; Oyama K; Ueda J; Sato H; Takahashi K; Taniue K; Okada T; Fujibayashi S; Hayashi A; Goto T; Enomoto K; Konishi H; Fujiya M; Miyakawa K; Tanino M; Nishikawa Y; Koga D; Watanabe T; Maeda C; Karasaki H; Liss AS; Mizukami Y; Okumura T J Gastroenterol; 2022 Mar; 57(3):208-220. PubMed ID: 35018527 [TBL] [Abstract][Full Text] [Related]